Cullinan Oncology, Inc. – NASDAQ:CGEM
Founder-led company
Cullinan Oncology stock price today
$7.51
-4.51
-37.52%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Cullinan Oncology stock price monthly change
-26.93%
month
Cullinan Oncology stock price quarterly change
-26.93%
quarter
Cullinan Oncology stock price yearly change
+19.25%
year
Cullinan Oncology key metrics
Market Cap | 676.89M |
Enterprise value | N/A |
P/E | 4.46 |
EV/Sales | N/A |
EV/EBITDA | -44.29 |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | 0.01 |
EPS | -3.15 |
Revenue | N/A |
EBITDA | -170.20M |
Income | -132.34M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCullinan Oncology stock price history
Cullinan Oncology stock forecast
Cullinan Oncology financial statements
Average Price Target
$34
Potential upside: 352.72%
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 0 | -32.21M | |
|---|---|---|---|
| Sep 2023 | 0 | -39.18M | |
| Dec 2023 | 0 | -23.80M | |
| Mar 2024 | 0 | -37.14M |
| 2024-03-14 | -0.96 | -0.54 |
|---|
| Jun 2023 | 521984000 | 22.41M | 4.29% |
|---|---|---|---|
| Sep 2023 | 494707000 | 25.89M | 5.23% |
| Dec 2023 | 485096000 | 31.20M | 6.43% |
| Mar 2024 | 449430000 | 23.76M | 5.29% |
| Jun 2023 | -31.00M | 12.11M | 38.60M |
|---|---|---|---|
| Sep 2023 | -34.14M | -42.95M | 112K |
| Dec 2023 | -18.13M | 51.47M | 248K |
| Mar 2024 | -38.24M | 12.95M | 1.08M |
Cullinan Oncology alternative data
| Aug 2023 | 62 |
|---|---|
| Sep 2023 | 62 |
| Oct 2023 | 62 |
| Nov 2023 | 62 |
| Dec 2023 | 62 |
| Jan 2024 | 62 |
| Feb 2024 | 62 |
| Mar 2024 | 85 |
| Apr 2024 | 85 |
| May 2024 | 85 |
| Jun 2024 | 85 |
| Jul 2024 | 85 |
Cullinan Oncology other data
82.54%
+3.03%
of CGEM is owned by hedge funds
37.64M
+769.35K
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 0 | 80000 |
| Feb 2024 | 0 | 40000 |
| May 2024 | 0 | 63606 |
| Jul 2024 | 0 | 8000 |
| Sep 2024 | 0 | 8000 |
| Nov 2024 | 0 | 8000 |
| Dec 2024 | 0 | 3489 |
Top 4 Immunology Stocks Poised For Growth In 2025
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
Cullinan Therapeutics: Casting A Wide Net With Their Pipeline
Cullinan Oncology: Inexplicably Trading Below Cash Despite Robust Data
Cullinan Oncology: Playing 'Moneyball' In The Drug Development Sector
Week In Review: China Biopharmas Announce 3 Out-Licensing Deals Totaling $2 Billion
ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years
Cullinan Oncology: One Of The Leaders In Cancer Treatment Development
-
What's the price of Cullinan Oncology stock today?
One share of Cullinan Oncology stock can currently be purchased for approximately $7.51.
-
When is Cullinan Oncology's next earnings date?
Unfortunately, Cullinan Oncology's (CGEM) next earnings date is currently unknown.
-
Does Cullinan Oncology pay dividends?
No, Cullinan Oncology does not pay dividends.
-
How much money does Cullinan Oncology make?
Cullinan Oncology has a market capitalization of 676.89M. Cullinan Oncology made a loss 153.16M US dollars in net income (profit) last year or -$0.54 on an earnings per share basis.
-
What is Cullinan Oncology's stock symbol?
Cullinan Oncology, Inc. is traded on the NASDAQ under the ticker symbol "CGEM".
-
What is Cullinan Oncology's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Cullinan Oncology?
Shares of Cullinan Oncology can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cullinan Oncology's key executives?
Cullinan Oncology's management team includes the following people:
- Dr. Patrick A. Baeuerle Ph.D. Co-Founder & Acting Chief Scientific Officer of Biologics(age: 67, pay: $737,930)
- Mr. Owen P. Hughes Jr. Strategic Advisor(age: 50, pay: $720,560)
-
Is Cullinan Oncology founder-led company?
Yes, Cullinan Oncology is a company led by its founder Dr. Patrick A. Baeuerle Ph.D..
-
How many employees does Cullinan Oncology have?
As Jul 2024, Cullinan Oncology employs 85 workers.
-
When Cullinan Oncology went public?
Cullinan Oncology, Inc. is publicly traded company for more then 4 years since IPO on 8 Jan 2021.
-
What is Cullinan Oncology's official website?
The official website for Cullinan Oncology is cullinanoncology.com.
-
Where are Cullinan Oncology's headquarters?
Cullinan Oncology is headquartered at One Main Street, Cambridge, MA.
-
How can i contact Cullinan Oncology?
Cullinan Oncology's mailing address is One Main Street, Cambridge, MA and company can be reached via phone at +61 74104650.
-
What is Cullinan Oncology stock forecast & price target?
Based on 2 Wall Street analysts` predicted price targets for Cullinan Oncology in the last 12 months, the avarage price target is $34. The average price target represents a 352.72% change from the last price of $7.51.
Cullinan Oncology company profile:
Cullinan Oncology, Inc.
cullinanoncology.comExchange:
NASDAQ
Full time employees:
85
Industry:
Biotechnology
Sector:
Healthcare
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer. Its preclinical products include CLN-049, a humanized bispecific antibody for the treatment of acute myeloid leukemia; CLN-619, a monoclonal antibody for the treatment of solid tumors; CLN-617, a fusion protein for the treatment of solid tumors; CLN-978, a T cell engaging antibody for B-cell malignancies; Opal, a bispecific fusion protein to block the PD-1 axis, and to activate the 4-IBB/CD137 pathway on T cells in tumors; and Jade, a cell therapy to target a novel senescence and cancer-related protein. The company has collaboration agreements with Cullinan Pearl Corp. to develop, manufacture, and commercialize CLN-081 and products containing CLN-081; and Adimab, LLC to discover and/or optimize antibodies. Cullinan Oncology, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
One Main Street
Cambridge, MA 02142
Cambridge, MA 02142
CIK: 0001789972
ISIN: US2300311063
CUSIP: 230031106
